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Abstract: Biotechnology, in a broad sense, comprises the manipulation of microorganisms, plants and animals, with the proposal to obtain 
processes and products of interest to society. Although the term appeared at the beginning of the 20th century, biotechnological processes 
have been present since ancient times in the production of fermented food and beverages. Biotechnology has also been present since the 
beginning of Medicine. Inhaling powder from sun-dried human smallpox wounds or using secretion of the udders of cows contaminated 
with bovine smallpox are examples of ancient techniques used as methods of immunization of the disease. In this sense, many treatments 
have emerged over time, such as vaccines, the production of penicillin, the first antibiotic and the production of insulin by recombinant DNA, 
which have revolutionized Medicine and enabled a better quality of life for humans. Many products and materials from Biotechnology are 
still emerging, such as scaffolds in Regenerative Medicine for bone tissue recovery, bacterial cellulose tubes used as artificial blood vessels, 
induced pluripotent stem cells and microphysiological systems, which promise to further improve modern Medicine and provide better 
techniques and therapies for various treatments.
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Introduction
Biotechnology, a word derived from the Greek bios (βίος) life; technos 
(τεχνηος) practice, and logos (λόγος) thought or study, is conceptually 
recognized as the union of Biology and Technology. However, there is 
no consensus about its definition and various ways of defining it can 
be found. According to Faleiro and Andrade,1 “in its broader meaning, 
Biotechnology is defined as the use of living beings, their parts or 
products for the production of goods and services”. According to the 
Brazilian Ministry of the Environment,2 “Biotechnologies, in its broadest 
sense, include manipulation of microorganisms, plants and animals, 
with a view to obtaining processes and products of interest to society”.
There is also a discussion on what is meant by classical and modern 
biotechnology. According to Brazilian Ministry of Industry, Foreign Trade 
and Services,3 classical Biotechnology refers to traditional processes such 
as fermentation, genetic improvement by selection, the use of living beings 
or their parts to produce goods and services. Modern Biotechnology, 
according to Faleiro and Andrade1 started with the discovery of DNA that 
enabled a revolution in the areas of Genetics and Molecular Biology.
Although the term Biotechnology appeared at the beginning of the 
20th century, the techniques of classical Biotechnology have been used 
for quite some time. It is estimated that fermentation processes for the 
production of food such as cheese and wine date back to 6000 BC by the 
Assyrians and Babylonians.1,4-6
Classical Biotechnology techniques were also used in antiquity for 
therapeutic purposes. The Chinese practice of inhaling dust from sun-
dried smallpox wounds and the use of bovine smallpox wound secretions 
to prevent human smallpox are good examples of these techniques.7,8
Objectives
The objectives of the present work focus on presenting a brief 
historical overview of the contributions of Biotechnology to human health 
and pointing out some future perspectives that may further improve 
Medicine and possibly provide new technologies and therapies for 
various treatments.
Methodology
A brief bibliographic survey was conducted in databases, books 
and scientific articles related to Biotechnology, its definitions and 
applications in the area of Medicine. In addition, numerical and statistical 
data cited in the present study were taken from sources and reports of 
national and international entities, as well as from scientific articles and 
websites present in the literature.
Literature Review
Variolation And The Origin Of Vaccines
The history of the emergence of vaccines is directly related to a 
very old disease, today practically eradicated: smallpox. There are 
ancient Egyptian, Indian and Chinese writings that already described 
the symptoms of the disease. In 1898 the mummy of Pharaoh Ramses 
V was discovered (dated 1157 BC) with signs of skin eruptions quite 
characteristic of people with this disease.9 Smallpox was responsible 
for the death of millions of people around the world. It is estimated that 
the disease prevailed in China and India around 1000 BC. However, the 
first recorded epidemic occurred in Arabia during the sixth century. 
The disease is believed to have spread throughout North Africa and 
Europe during the sixth, seventh and eighth centuries9 as a result of Arab 
invasions. According to Behbehani,9 the disease was reintroduced in 
Europe due to the Crusades, which occurred between the years 1096 
and 1291, and stayed there. During the 18th century, smallpox was 
estimated to have been responsible for the deaths of approximately 
400,000 people a year in Europe and caused about a third of all blindness 
on the continent.
Variolation was one of the first techniques of smallpox immunization. 
The method was practiced in different ways by different people. 
However, in short, the practice consisted of the same principles, which 
promoted the contact of healthy people with parts of wounds or pustules 
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of contaminated people in the hope of developing a milder form of the 
disease, and so becoming immune.10 More than 500 years ago in China, 
sun-dried smallpox wounds were used to prevent the disease. The 
method was based on the exposure of pathogens to solar radiation that 
weakened them. Thus, when inhaling the powder obtained, the body 
would come into contact with a more harmless version of the virus and 
become immune.7,9 Variolation has been reported in Persia where dry 
pustules powder was taken as a form of immunization. In Greece, Turkey, 
Arabia, North Africa and the Caspian Sea region, the practice consisted 
of rubbing pustules from wounds on the scratched skin of children.9
It was only after the emergence of a safer and more efficient method 
of smallpox prevention that variolation was left aside. During his studies, 
around 1780, Edward Jenner observed that bovine smallpox could 
immunize people from the human version of the disease. According 
to Behbehani,9 Jenner heard from a dairy patient who treated pustular 
wounds on her skin that her disease, although similar, could not be 
smallpox because she had already been contaminated with bovine 
smallpox. This was a very popular knowledge among local farmers. Thus, 
Edward Jenner discovered, by performing several tests, the efficiency of 
using wound secretions present in udders of cows contaminated with a 
specific type of bovine smallpox (because he observed other variations 
attributed to the same disease in cattle) in the immunization of human 
smallpox. Therefore, he developed a method very similar to variolation, 
but using secretions from cows, and the first vaccine appeared, a term 
derived from the Latin vaccinus which means “derived from the cow”.9,11,12
During the 19th century, vaccination against smallpox became a 
worldwide practice, especially in Europe and North America, but the 
principles learned from Jenner’s results remained dormant for more than 
a century and a half, during which no new vaccines appeared. Despite 
being shown to be effective in immunization, Jenner’s vaccine suffered 
protests and objections from the population and the church, as the 
possibility of death of the inoculated was recognized (from two to three 
deaths out of every 100 inoculated individuals). In addition, there was 
the fear on part of the population that this operation consisting in the 
introduction of material extracted from cows would transfer bovine char-
acteristics, such as bovine features, birth of horns and mooing, to the 
“vaccinated”. Thus, it was necessary to increase the reliability of vaccines 
and eliminate the idea that diseases would be “divine punishment”.11,13,14 
Figure 1 shows a James Gillray’s cartoon drawn at 1802 which demon-
strates the population’s concern about Jenner’s vaccines.15
Much of this disbelief was due to ignorance of the cause of the 
diseases. Even at that time, experiments were being conducted to obtain 
evidence that would discredit the theory of spontaneous generation in 
favor of the germinal theory of the disease. Louis Pasteur and Robert 
Koch, however, developed research that could prove that infectious 
diseases were caused by microorganisms.11,13,14,16
Pasteur, by studying the metabolism of microorganisms, has 
discovered ways of transforming pathogens to produce vaccines and 
other new ways of preventing and treating infections. Thus, techniques 
such as the attenuation or inactivation of pathogens that enabled the 
immunization of several diseases, such as rabies, typhoid fever, cholera 
and black plague (bubonic plague)13 have emerged.
Penicillin discovery
Another great contribution of Biotechnology to modern Medicine is 
the production of penicillin, the first antibiotic. The world’s population, 
especially in Europe and Asia, has suffered several cases of pandem-
Figure 1 - English charge from the 19th century showing people acquiring bovine characteristics after immunization. Source: The British Museum15. 
Image in the public domain.
ic in the pre-antibiotic era. It is estimated that the black plague alone, 
caused by the bacteria Yersinia pestis, was responsible for at least three 
pandemics in history, causing almost 100 million deaths in Europe and 
the outbreak between 1895 and 1930, with about 12 million victims, 
mainly in India.16
For thousands of years, when nothing was known about the cause 
of infections, prevention methods, antibiotics, and vaccination, mankind 
was tortured by massive epidemics such as syphilis, smallpox, malar-
ia, typhoid, yellow fever, leprosy, tuberculosis, Spanish flu, cholera, and 
black plague, to name only a few examples.16
The accidental discovery of penicillin in 1928 by the English physician 
Alexander Fleming17 inaugurated a new era in Medicine, since infectious 
diseases that would normally lead to death could be cured. Penicillin is 
a substance secreted by the fungus Pennicilium and has proven to be 
more efficient in controlling bacterial proliferation compared to chemical 
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substances used at the time, such as salvarsan (used in the treatment of 
syphilis), proflavine (widely used in World War II, mainly in deep wounds) 
and sulfas or sulfonamides (prontosil).18 However, the antibiotic was only 
introduced as a therapeutic agent in the 1940s. After the process of in-
dustrialization of penicillin, especially as a consequence of World War II, 
a rapid growth was observed in the discovery and development of new 
antibiotics.18
Diabetes and the production of human insulin by recombi-
nant DNA
The production of synthetic insulin by transgenic microorganisms 
was also a major milestone in biotechnology in the field of Medicine for 
the treatment of diabetes. Diabetes mellitus is a very old disease. There 
are records of his symptoms dating from 1500 BC, such as frequent 
and abundant diuresis, uncontrollable thirst and marked weight loss as 
its main clinical manifestations. Aretaeus, a Roman physician, created 
the term diabetes which means “going through” because of excessive 
diuresis, one of its most evident symptoms.19,20
It was only in 1889 that Joseph von Mering and Oskar Minkowsky, 
during their research on fat digestion, observed that removing the 
pancreas from dogs triggered very similar symptoms of the disease. 
In 1908, the scientist Georg Zuelzer developed the first injectable 
pancreatic extract that suppressed glycosuria, but this therapeutic 
modality did not evolve due to its adverse effects.19,20
Insulin was isolated from pancreatic extract in 1921 by Frederick 
Banting and Charles Best in the laboratory of physiologist John Macleod. 
The first test for decreased glycosuria and ketonuria was performed in 
1922 by injecting 15 mL of pancreatic extract in a 14-year-old patient. 
However, the effect obtained was lower than expected, in addition to 
causing abscesses at the place of application. Only after purification of 
the extract by biochemist James Bertram Collip, which had the desired 
effect immediately. The discovery of the relationship between pancreatic 
secretion and diabetes mellitus earned the Nobel in Medicine and 
Physiology due to this therapeutic achievement.19,20
The first commercially produced insulin, the regular insulin or 
insulin R, extracted from animals, has a rapid mechanism of action, 
which required several applications throughout the day yielding several 
complaints from patients. Thus, other types of insulins with longer 
action time were produced, such as NPH insulin (neutral protamine 
Hagedorn), with addition of protamine basic protein, and PZI insulin 
(protamine zinc insulin) with addition of zinc in its composition. However, 
in clinical practice, different complications of the use of these insulins 
were observed, such as allergic conditions, lipodystrophy at the sites 
of application and, most importantly, immunological resistance to 
insulin.19,20
With the advancement of Molecular Biology, the era of human 
biosynthetic insulins began. Its principle is based on the genetic 
modification of bacteria to induce the production of the hormone used 
in the treatment of diabetes. The technique has five general procedures: 
to fractionate the DNA in specific locations using restriction enzymes; to 
unite DNA fragments in a covalent way (DNA ligase); to select a DNA for 
cloning vector, that is, that can self-replicate; to transfer the DNA to a 
host cell; and to select the cells with the recombinant DNA. The bacteria 
Escherichia coli was the first organism used for rDNA work and is still the 
most common host cell.21
Biotechnology perspectives for the medicine of the future
Regenerative Medicine
With the development of techniques and new biotechnological 
materials, the prospects for health are very promising. In particular, 
the use of bacterial cellulose in the production of scaffolds (three-
dimensional matrices for cell growth) with potential application in 
Regenerative Medicine stands out.
Regenerative Medicine is a branch of Medicine that proposes to 
restore or replace cells, tissues and organs to recover their functionality. 
According to Porcellini,22 it is a very recent area, it appeared in 1997 
when Whitman et al.23 proposed the integration of platelet-rich plasma 
adhered to fibrin for possible maxillary bone regeneration. One year 
later, Marx et al.24there was also a greater bone density in grafts in which 
platelet-rich plasma was added (74.0% ± 11% demonstrated that platelet 
rich plasma is capable of inducing mandibular bone regeneration.24
Bone regeneration consists of the treatment of conditions such 
as trauma, osteosarcoma (primary bone tumor), osteomyelitis (severe 
infection of bone tissue) and osteitis (inflammation of bone tissue), 
and has been a major challenge in surgical practice. Many therapeutic 
approaches such as allografts (transplantation between different 
individuals of the same species), xenografts (surgical transplantation 
between individuals of different species), autografts (transplantation 
taken from the individual himself) and artificial grafts have been employed 
to restore bone function. However, such approaches have limitations, 
such as the low amount of bones donated or removed from the patient, 
risk of immune system response, possible infections and death of tissues 
that hinder their application. In addition, synthetic prostheses are hardly 
capable of mimicking true bones and interacting well with surrounding 
bone tissues, which can cause some fatigue.25 Therefore, Biotechnology 
applied to bone regeneration has proven to be very promising, especially 
scaffolds in Tissue Engineering. The scaffolds can promote different 
types of mechanisms for bone regeneration such as osteoconduction 
(ability to stimulate the growth of new tissues on the surface and 
pores of the implant, promoting adherence and proliferation of cells to 
form new vascularized bone tissue), osteoinduction (ability to attract 
immature cells and induce them to transform into bone tissue forming 
cells; in general, induce cells to bone formation in ectopic medium by 
biomolecular signaling mechanisms) and osseointegration (integration 
between bone tissue cells and the implant occurs by adhesion of cells on 
the surface of the implanted material).25
The bone has a very complex biomechanical system, which requires 
from the scaffolds specific properties that to promote this restoration 
such as biocompatibility, mechanical properties similar to bone 
structure, adequate porosity that allows the vascularization of bone 
tissue (between 200 and 350 μm) and bioabsorbability/biodegradability. 
Thus, scaffolds that use bacterial cellulose have shown to be very 
promising for bone regeneration, since they have the ideal properties 
required for such application.25
Torgbo and Sukyai’s review paper25 cites several materials based 
on bacterial cellulose with potential application in bone regeneration, 
such as a Huang et al. work,26 which produced a scaffold bacterial 
cellulose/hydroxyapatite agarose gel that was able to promote adhesion, 
proliferation and cell viability in the osteogenic process of human bone 
marrow stem cells.
Another area of Regenerative Medicine that will benefit from 
new biotechnological materials is the production of artificial blood 
vessels. According to data from the World Health Organization (WHO), 
cardiovascular disease is the leading cause of mortality worldwide. It 
is estimated that in 2016 alone they caused the death of approximately 
17.9 million people worldwide, about 30% of all deaths.27 According to 
the study and Lee and Park,28 about 600 thousand surgical procedures 
are performed worldwide every year.
Such a demand, according to Schumann et al.,29 caused the 
widespread use of artificial grafts with those of polyethylene terephthalate 
and expanded polytetrafluoroethylene (PTFE). However, in small diameter 
grafts (< 6 mm) the occlusion rate and consequent thrombosis was 40% 
of the cases in less than six months of implantation. The occlusion of 
artificial vessels is associated with blood interactions with synthetic 
materials that cause obstruction. In addition, artificial materials increase 
the risk of bacterial infections and can cause widespread rejections and 
inflammation.
Considering the natural grafts, implants have been performed using 
the saphenous vein in revascularization processes, such as the internal 
mammary vein in autologous graft. However, the procedure is not totally 
adequate, since, because it is small, the graft may present varicosity. 
Thus, the search for new implants of small diameter, biocompatible and 
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in which inclusion does not occur is of great importance.
Bacterial cellulose presents characteristics such as mechanical 
properties (Young 134 GPa module and tensile strength of 2 GPa 
per fiber), high purity, microstructure that allows the adhesion and 
proliferation of cells and biocompatibility relevant for the production of 
artificial blood vessels.
The work of Schumann et al.29 proposes bacterial cellulose blood 
vessel transplants in vivo as a replacement for carotid arteries in five rats, 
with a 1 mm inner cavity, which were allowed to grow for one year. They 
were also implanted in eight pigs, weighing between 35-40 kg, in which 
they were administered in carotid arteries that had free access to food 
and were allowed to grow for three months. The animals were sacrificed 
and the implants were evaluated for resistance to blood pressure of 70 
mmHg and vessel obstruction.
In the rats, it was observed that at the contact site between the 
prosthesis and the newly formed blood vessel, the presence of active 
fibroblasts that produce collagen, necessary for the integration and 
adequacy of synthetic vessels to the body of the animal, was verified. 
Furthermore, in all one-year-old animals, there was no obstruction of 
any synthetic artery. It is estimated that the high permeability rate may 
be favored by the targeted nature of BASYC fibers, which facilitate blood 
flow.
In pigs, on the other hand, the rate of permeability of the grafts 
was 87.5% (1 out of 8 grafts was found obstructed). It is believed that 
the obstruction may have occurred due to the circundant tissue that 
did not adhere correctly to the graft. However, no type of narrowing of 
the artificial arteries (stenosis) and no type of anastomosis (network 
of channels that bifurcate) were identified. It is also noteworthy that 
there were no apparent changes in any of the grafts, including dilation 
(aneurysm), dehiscence (natural fissure) and fistulas (inappropriate 
connections of distinct tissues and organs).
Induced pluripotent stem cells
Modern biotechnology techniques are also emerging and have 
great potential for various areas of Medicine. One such procedure is the 
production of induced pluripotent stem cells (iPSC).
The interest in pluripotent cells consists in the treatment of tissues, 
organs injured or destroyed, so they can be a route for the treatment of 
Parkinson’s disease, spinal cord injuries and diabetes.31
Currently, stem cell treatments suffer a major ethical impact from the 
use of human embryos in the process. Moreover, there is a concern that 
immunological rejection could occur in treatments. Stem cells can be 
classified into two main types: embryonic and nonembryonic. Embryonic 
stem cells have the characteristic of being pluripotent, that is, they can 
form any type of cell in the three germ layers (endoderm, mesoderm 
and ectoderm), while nonembryonic stem cells are capable of forming 
several types of tissues, that is, they are multipotent and can be extracted 
from some tissues or organs such as the placenta, umbilical cord, bone 
marrow, peripheral blood.
Initially obtained in the work of Takahashi and Yamanaka30 using 
cultures of embryonic and adult fibroblasts of mouse, iPSCs were 
produced in vitro by gene reprogramming of somatic cells through 
four transcription factors that induce them to acquire properties 
similar to embryonic stem cells. The hypothesis was based on nuclear 
reprogramming based on oocyte genes (oocytes II), which maintain 
embryonic pluripotent property for a long time. Through retroviral 
vectors, exogenous genes are introduced into somatic cells and induce 
endogenous expression of pluripotency. In addition, exogenous factors 
that have key roles in cell differentiation are silenced and the pluripotent 
state becomes completely dependent on the endogenous transcriptional 
circuit.30,31
The induced pluripotent stem cells produced in the work of Takahashi 
and Yamanaka30 were subcutaneously transplanted in immunodeficient 
mice; tumors with cells of the three types of embryonic tissues were 
found, indicating that the induction of somatic cells to obtain pluripotent 
properties was effective. The work won the authors a Nobel Prize.
According to Reis et al.,31 gene reprogramming has been performed 
using human skin fibroblasts with the use of viral vectors. However, due 
to the difficulty in obtaining epithelial tissue due to the need for biopsy, 
some recent studies indicate that other human cells are being used for 
the production of iPSC, such as adipose tissue stem cells, hepatocytes, 
peripheral blood lymphocytes, among others, which can enable various 
treatments and avoid rejection reactions by using the patient’s own 
cells.33
Microphysiological systems
Still thinking about iPSC applications and the use of 3D supports for cell 
culture (scaffolds), the work of Edington et al.33 addresses the production 
of microphysiological systems (MPSs) that mimic physiological functions 
in vivo through specialized culture microenvironments to perform drug 
testing in vitro.
Known as “human body in chip” or “organs in tablets”, the 
microphysiological systems are microenvironments of specialized 
cell cultures, which in 3D matrices (scaffolds) interconnected by 
microperfusion channels seek to simulate the physiological functioning 
of the human body. They are being developed to supply the demand in 
pre-clinical pharmacology for more effective models for toxicity testing 
and drug safety. Currently, animal models used delay the development 
of treatments and are not very safe in predicting the safety and efficacy of 
drugs in humans, causing billions of dollars lost each year.33
However, the production of multifunctional microphysiological 
systems is still under development and presents some technical 
challenges to be overcome, as described by Edington et al.:33
(i) creation and maintenance of MPSs that exhibit sufficiently 
representative and robust physiological function in periods of 
prolonged culture, typically requiring intensive procurement 
and preparation of primary cells or pluripotent stem cells 
(PSCs) to achieve functional maturity in specialized microen-
vironments;
(ii) Design and manufacture of platform-shaped equipment 
that can accommodate and sustain the relevant MPS - in-
cluding off-platform transfer to the platform in the case of 
MPS requiring disparate maturation times and complex 
means of maturation - by fluidically linking them in a manner 
that is permissive to quantitative analysis of biological phe-
nomena involving the fate of drugs or disease phenomena;
(iii) selection of an average composition compatible with the 
different MPS on the platform;
(iv) a variety of other practical and translational aspects, in-
cluding flow separation, flow rates, physiological.
Figure 7 is a schematic representation of the functioning of micro-
physiological systems.33
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Conclusions
Biotechnology has long contributed to the maintenance of human 
health. From the production of forms for mass immunization, such as 
vaccines, to the production of revolutionary drugs, such as penicillin, to 
the production of human insulin for the treatment of diabetes, Biotech-
nology has enabled an increase in the quality of life of man and helped 
in the development of the society we know. Even today, biotechnologi-
cal processes and materials have been developed with the objective of 
meeting the demand for new products and services to further improve 
the procedures applied in modern Medicine. The production of scaffolds 
applied to the regeneration of tissues and organs, induced pluripotent 
stem cells and microphysiological systems, are just some of the technol-
ogies that can further improve Medicine and provide better technologies 
and therapies for several treatments.
Therefore, the importance of Biotechnology for contemporary so-
ciety is undeniable, since it would be difficult to progress without the 
contribution of this important area.
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